Lee T, Paquet M, Larsson O, Pelletier J
Department of Biochemistry, McGill University, Montreal, Quebec, Canada.
Département de Pathologie et Microbiologie, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, Québec.
Oncogene. 2016 Sep 29;35(39):5093-105. doi: 10.1038/onc.2016.52. Epub 2016 Mar 14.
The NTP-dependent DExH/D-box helicase DHX9 is a key participant in a number of gene regulatory steps, including transcriptional, translational, and microRNA-mediated control, DNA replication and maintenance of genomic stability. DHX9 has also been implicated in tumor cell maintenance and drug response. Here we report that inhibition of DHX9 expression is lethal to human cancer cell lines and murine Eμ-Myc lymphomas. Using a novel conditional shDHX9 mouse model, we demonstrate that sustained and prolonged (6 months) suppression of DHX9 does not result in any deleterious effects at the organismal level. Body weight, blood biochemistry and histology of various tissues were comparable to control mice. Global gene expression profiling revealed that, although reduction of DHX9 expression resulted in multiple transcriptome changes, these were relatively benign and did not lead to any discernible phenotype. Our results demonstrate a robust tolerance for systemic DHX9 suppression in vivo and support the targeting of DHX9 as an effective and specific chemotherapeutic approach.
依赖NTP的DExH/D框解旋酶DHX9是许多基因调控步骤的关键参与者,包括转录、翻译和微小RNA介导的调控、DNA复制以及基因组稳定性的维持。DHX9也与肿瘤细胞的维持和药物反应有关。在此我们报告,抑制DHX9的表达对人类癌细胞系和小鼠Eμ-Myc淋巴瘤具有致死性。使用一种新型的条件性shDHX9小鼠模型,我们证明持续且长期(6个月)抑制DHX9在机体水平上不会导致任何有害影响。各种组织的体重、血液生化指标和组织学与对照小鼠相当。全基因组表达谱分析显示,虽然DHX9表达的降低导致了多个转录组变化,但这些变化相对良性,并未导致任何可识别的表型。我们的结果证明了体内对系统性抑制DHX9具有强大的耐受性,并支持将DHX9作为一种有效且特异性的化疗方法进行靶向治疗。